Hadassah

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

Monday, Oct 24 2011

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

BreathID, a noninvasive early diagnosis device for acute liver failure developed at the Hadassah University Medical Center, has obtained a United States Food and Drug Administration (FDA) Humanitarian Device Exemption, which provides a fast-track toward approval. Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine A is Medical Director of BreathID's developer, Exalenz Bioscience Ltd., a startup company of Hadasit, Hadassah's technology transfer arm.

The device, as well as saving lives through early diagnosis, can lead to the elimination of unnecessary liver transplants. The humanitarian use device (HUD) designation which BreathID received means that the device does not have to undergo an efficacy trial, thereby greatly shortening the approval process if it meets FDA requirements. BreathID's effectiveness in diagnosing acute liver failure was demonstrated in a trial of several dozen patients at Hadassah and London's Kings College.
The FDA has already approved a clinical trial of the BreathID device for the early diagnosis of Hepatocellular Carcinoma, a liver cancer.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 13 2019

Alzheimer’s Further Illuminated at Hadassah with New Exclusive Imaging Agent

The Hadassah Medical Organization, through its subsidiary SRY, has contracted to be the sole Israeli agent for General Electric to produce Vizamy, the company’s new radioactive imaging agent to detect, at an early stage, amyloid plaque, which has been linked to the development of Alzheimer’s disease.

READ MORE ›
alt_text

Friday, Aug 2 2019

New Thyroid Eye Disease Clinic at Hadassah Brings Integrated Care to New Mom

Miriam, 34, had just given birth to her third child, and, unlike the joy she felt after her first two births, she felt awful.

READ MORE ›
alt_text

Friday, Aug 2 2019

Eloxx Pharmaceuticals Announces New Drug Application for Clinical Trial in Cystic Fibrosis Patients

Professor Eitan Kerem, head of the Division of Pediatrics at the Hadassah Medical Organization, will serve as the Global Lead Investigator for this clinical trial.

READ MORE ›
alt_text

Wednesday, Jul 31 2019

Skin Cancer Treatment Enhanced in New Center for Dermatologic Surgery

Thanks to a donation by the Israeli businessman and philanthropist Morris Kahn, a major supporter of the Israeli moon spacecraft “Beresheet,” Hadassah Hospital Ein Kerem has just opened the new Center for Dermatologic Surgery, which offers Mohs surgery for patients with common types of skin cancer.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More